The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders;Rola niedoboru inozytolu w patofizjologii zaburzeń wystȩpuja̧cych w zespole policystycznych jajników

Ginekologia Polska

Volumn 85, Issue 1, 2014, Pages 54-57

  Jakimiuk, Artur J ^a,b   Szamatowicz, Jacek ^c  

^a Chorób Kobiecych i Ginekologii Onkologicznej CSK MSW   (Poland)

^b Centralny Szpital Kliniczny Ministerstwa Spraw Wewn trznych   (Poland)

^c Uniwersytetu Medycznego   (Poland)

Author keywords

Insulin resistance; Myo inositolo; Polycystic ovary syndrome

Indexed keywords

FOLIC ACID; INOSITOL; VITAMIN B COMPLEX;

ARTICLE; DRUG EFFECT; FEMALE; FOLLICULAR PHASE; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; OVARY; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); WOMEN'S HEALTH;

BLOOD GLUCOSE; FEMALE; FOLIC ACID; FOLLICULAR PHASE; HUMANS; INOSITOL; OVARY; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX; WOMEN'S HEALTH;

EID: 84896844961     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1691     Document Type: Article

References (34)

1. March WA, Moore VM, Willson KJ, [et al.]. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010, 25 (2), 544-551.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004, 81 (1),19-25.
3. Goodarzi MO, Jones MR, Chen YD, Azziz R. First evidence of genetic association between AKT2 and polycystic ovary syndrome. Diabetes Care. 2008, 31 (12), 2284-2287.
4. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006, 12 (7), 324-332.
5. Holte J, Bergh T, Berne C, [et al.]. Enhanced early insulin response to glucose in relation to insulin resistance inwomen with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab. 1994, 78 (5), 1052-1058.
6. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003, 24 (5), 633-667.
7. Azziz R, Ehrmann D, Legro RS, [et al.]. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebocontrolled trial. J Clin Endocrinol Metab. 2001, 86 (4), 1626-1632.
8. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrateresistant polycystic ovary syndrome. Fertil Steril. 2006, 85 (2), 428-435.
9. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010, 16 (11-12), 543-552.
10. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012, 28 (7), 509-515.
11. Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002, 3 (1), 47-60.
12. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem. 1999, 274, 1865-1868.
13. Beeson M, Sajan MP, Dizon M, [et al.]. Activation of protein kinase C-zeta by insulin and phospha-tidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003, 52, 1926-1934.
14. Dash S, Sano H, Rochford JJ, [et al.]. A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc Natl Acad Sci USA. 2009, 106, 9350-9355.
15. Cohen P. The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol. 2006, 7 (11), 867-873. Review.
16. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010, 16 (11-12), 543-552.
17. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013, 95 (10), 1811-1827.
18. Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A. 1993, 90 (13), 5924-5928.
19. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, [et al.]. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006, 29 (2), 300-305.
20. Baillargeon JP, Nestler JE, Ostlund RE, [et al.]. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. 2008, 23 (6), 1439-1446.
21. Villeneuve MC, Ostlund RE Jr, Baillargeon JP. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity. Metabolism. 2009 Jan;58(1):62-8. doi: 10.1016/j.metabol.2008.08.007.
22. Beemster P, Groenen P, Steegers-Thunissen R. Involvement of inositol in reproduction. Nutr Rev 2002, 60, 80-87
23. Homburg R. Polycystic ovary syndrome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996, 11, 29-39
24. Ciampielli M, Fulghesu AM, Cucinelli F et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metab Clin Exp 1999, 48, 167-172
25. Genazzani AD, Battalgia C, Malavasi B et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function nonobese patients with polycystic ovary syndrome. Fertil Steril 2004,81,114-119
26. Coady MJ, Wallendorf B, Gagnon DG et al. Indentification of a novel Na+/myo-inositol cotransporter. J Biol Chem 2002,227,35219-35224
27. Genazzani AD, Lanzoni C, Ricchieri F et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008,24,139-144
28. Constatino D, Minozzi G, Ninozii E et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009,13,105-110
29. Gerli S, Mignosa M, Di Renzo GC et al. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controled trial. Eur Rev Med Pharmacol Sci 2003,7,151-159
30. Raffone E, Rizzo P, Benedetto V. Insulin sensitizer agents alone and in co-treatment with rFSH for ovulation induction I PCOS women. Gynecol Endocrinol 2010,26,275-280
31. Papaleo E, Unfer V, Baillargeon JP et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009, 91, 1750-1754
32. Lisi F, Carfagna P, Oliva MM et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 2012, 10, 52 doi:10.1186/1477-7827-10-52
33. Gennazani AD, Prati A, Santagni S et al. Diferential insulin response to myo-onositol administration on obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012, 27,1473-1477
34. Artini A, Berardino F, Papini F et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013, 29, 375-379